African tick-bite fever in French travelers.
Of the 34 travelers, 30 completed the questionnaire and 20 consented to give at least 1 serum sample. After their return to France, symptoms compatible clinically with ATBF developed in 10 of the travelers (Table) and 9 had positive serologic results and/or a seroconversion for spotted fever group-rickettsia, including R. africae (Table). The median time from illness onset to serum testing was 19 days. Thus, 9 of the travelers had probable and 1 had possible (no serum was available) ATBF. Including both probable and possible cases, the illness rate for the whole group was 33.3% (10/30). None of the travelers reported a history of tick bite. The delay between probable exposure and onset of symptoms was 3-10 days (mean [+ or -] standard deviation 6.1 [+ or -] 1.9 days). Multiple eschars on the legs or arms were seen in 7 (70%) of 10 patients. Eight patients received doxycycline (200 mg per day) for a mean of 10.8 [+ or -] 5.9 days (range 5-20), 1 patient received pristinamycin for 8 days, and 1 patient received no treatment. All patients recovered fully without sequela; however, 6 patients reported convalescent-phase asthenia and 1 reported chronic insomnia, which had not occurred previously, for 2 months after the illness. Among the 10 remaining travelers, for whom a serum sample was available, with no clinical evidence of ATBF, 5 were positive for R. africae with only immunoglobulin M (IgM) at a titer of 1:32 in 4 cases and IgG at 1:128 with IgM at 1:32 in 1 case (an acute-phase serum from this patient showed IgG at 1:32 and IgM at 1:32). The 5 other travelers had negative serologic results. Results of serologic testing for other bacteria were negative for all travelers. Twenty-four travelers (80%), including the 10 symptomatic patients, reported using topical insect repellent daily.
Most cases of ATBF are reported in clusters of travelers exposed to ticks during game hunting or safaris, as described here (1,3-5). The estimated incidence of African tick-bite fever in safari travelers is 4%-5.3% (4) but higher incidence may be reported as emphasized in our study. In our study, epidemiologic and clinical data for the 10 symptomatic patients were obtained in accordance with current knowledge of ATBF (2).
Skin biopsy samples remain the best tool to isolate or detect R. africae (2,6). However, specific serologic tests, especially immunofluorescence assays, remain the most widely used microbiologic test worldwide (7). No commercially available test for ATBF exists but due to extensive cross-reactions between spotted fever group rickettsiosis, commercial kits based on the detection of R. conorii antibodies can be used for the diagnosis of ATBF. Most tourists reported using topical insect repellents without any efficacy. Applying repellents to exposed skin provides little protection against ticks because they can crawl underneath clothing and bite untreated portions of the body (8). Thus, treating clothing with synthetic pyrethroid insecticide is recommended to complement the topical repellant (8).
In conclusion, our study emphasizes the importance of ATBF as a common cause of flulike illness in travelers returning from South Africa, but with a higher rate than malaria, typhoid fever, or other tropical fevers. The most important clinical clues are the presence of clustered cases with multiple inoculation eschars. Healthcare professionals who are providing advice should inform persons traveling to endemic areas of Africa of the risk of contracting ATBF and the importance of protecting themselves against tick bites. Chemoprophylaxis with doxycycline is not recommended, however, this recommendation may be evaluated in future clinical trials.
We thank Paul Newton for English corrections.
Paul H. Consigny, * Jean-Marc Rolain, ([dagger]) Daniel Mizzi, ([double dagger]) and Didier Raoult ([section])
* Institut Pasteur de Paris, Paris, France; ([dagger]) Universite de la Mediterranee, Marseille, France; ([double dagger]) Medecin de Sante au Travail, Plaisir, France; and Faculte de Medecine, Marseille, France
(1.) Raoult D, Fournier PE, Fenollar F, Jensenius M, Prioe T, de Pina JJ et al. Rickettsia africae, a tick-borne pathogen in travelers to sub-Saharan Africa. N Engl J Med. 2001;344:1504-10.
(2.) Jensenius M, Fournier PE, Kelly P, Myrvang B, Raoult D. African tick bite fever. Lancet Infect Dis. 2003;3:557-64.
(3.) Fournier PE, Roux V, Caumes E, Donzel M, Raoult D. Outbreak of Rickettsia africae infections in participants of an adventure race from South Africa. Clin Infect Dis. 1998;27:316-23.
(4.) Jensenius M, Fournier PE, Vene S, Hoel T, Hasle G, Henriksen AZ et al. African tick bite fever in travelers to rural sub-Equatorial Africa. Clin Infect Dis. 2003;36:1411-7.
(5.) McQuiston JH, Paddock CD, Singleton J Jr., Wheeling JT, Zaki SR, Childs JE. imported spotted fever rickettsioses in United States travelers returning from Africa: a summary of cases confirmed by laboratory testing at the Centers for Disease Control and Prevention, 1999 2002. Am J Trop Med Hyg. 2004;70:98-101.
(6.) Pretorius AM, Birtles RJ. Rickettsia mongolotimonae infection in South Africa. Emerg Infect Dis. 2004;10:125-6.
(7.) La Scola B, Raoult D. Laboratory diagnosis of rickettsioses: current approaches to the diagnosis of old and new rickettsial diseases. J Clin Microbiol. 1997;35:2715-27.
(8.) Parola P, Raoult D. Tick-borne bacterial diseases emerging in Europe. Clin Microbiol Infect. 2001;7:80-3.
Address for correspondence: Didier Raoult, Unite des Rickettsies, Faculte de Medecine, 27, Boulevard Jean Moulin, 13385 Marseille CEDEX 5, France; fax: 33-04-91-38-77-72; email: Didier.Raoult@medecine.univ-mrs.fr
All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.
Table. Epidemiologic, clinical, and serologic information for 10 patients with African tick-bite fever * Delay Sex/age Tick before Patient (y) bite onset (d) Fever Headache 1 M/62 No 7 Yes No 2 F/58 No 6 Yes No 3 M/58 No 6 No Yes 4 F/51 No 6 No Yes 5 M/58 No 5 Yes No 6 F/57 No 5 No No 7 M/65 No 5 Yes Yes 8 F/59 No 10 No No 9 M/53 No 3 Yes Yes 10 M/51 No 8 Yes No Total (%) 0 60 40 Skin 1st serum ([dagger]) Patient Myalgia Eschar (site) rash IgG/IgM 1 No Multiple (legs) No NA 2 Yes Multiple No 64/32 (legs, arms) 3 No Single (trunk) No 64/32 4 Yes Multiple No 0/64 (legs, trunk) 5 Yes Multiple (legs) No 512/0 6 Yes Yes Yes NA (unknown) 7 Yes Multiple No 128/64 (hands) 8 No Multiple (legs, No 64/8 arms, trunk) 9 Yes Multiple (legs) Yes 0/0 10 Yes No Yes 32/32 Total (%) 70 90 30 2nd serum ([dagger]) Patient IgG/IgM Diagnosis 1 NA Probable 2 64/128 Confirmed 3 128/16 Confirmed 4 128/16 Confirmed 5 512/0 Confirmed 6 32/16 Confirmed 7 512/128 Confirmed 8 128/32 Confirmed 9 1,024/512 Confirmed 10 64/64 Confirmed Total (%) * NA, not available; Ig, immunoglobulin, male-to-female ratio, 60%; mean age = 57.2 [+ or -] 4.5 years. ([dagger]) Identical results obtained with both Rickettsia africae and R. conorii antigens.
|Printer friendly Cite/link Email Feedback|
|Publication:||Emerging Infectious Diseases|
|Article Type:||Letter to the Editor|
|Date:||Nov 1, 2005|
|Previous Article:||Neonatal Moraxella osloensis ophthalmia.|
|Next Article:||Microbe: Are We Ready for the Next Plague?|